Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD) before working capital and other adjustments Read the full story
Tag Archive | "Baxter"
Rockwell forms a biotech partnership with Baxter for $45 million
Posted on 06 October 2014
Baxter International gave kidney drug developer Rockwell Medical a big boost in the form of $45 million in graduated payments in a biotech partnership. Read the full story
Baxter and Merrimack ink a pharma licensing deal for developing cancer drug
Posted on 25 September 2014
Baxter International had entered into an exclusive pharma licensing and collaboration agreement with Merrimack Pharmaceuticals to develop and commercialize lead cancer drug MM-398. Read the full story
Big pharma, Baxter sells its vaccines for $635 million
Posted on 31 July 2014
Big pharma, Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer for a total cash consideration of $635 million, subject to certain adjustments. Read the full story
M&A news: Baxter has acquired AesRX
Posted on 10 July 2014
In today's m&a news, Baxter International announced the acquisition of AesRx. Read the full story
Top 50 Pharma (top pharmaceutical companies)
Posted on 01 June 2014
The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
Baxter
Posted on 13 May 2014
Baxter is a top pharmaceutical company based in Deerfield, Illinois, USA Read the full story
Merger & acquisition between Baxter and Chatham Therapeutics
Posted on 03 April 2014
Baxter International has agreed for merger & acquisition for Chatham Therapeutics for $70 million. Read the full story
Big Pharma, Baxter International, plans to split itself in two
Posted on 28 March 2014
Big Pharma, Baxter International announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Read the full story
Baxter enters into a biotech deal for hemophilia
Posted on 31 January 2014
Baxter International has restructured its ongoing biotech deal with Xenetic Bioscience for the development of BAX 826 to assess its potential to extend the half-life and duration of effectiveness.
